The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Prevention of bone loss and hypoestrogenic symptoms by estrogen and interrupted progestogen add-back in long-term GnRH-agonist down-regulated patients with endometriosis and premenstrual syndrome
Abstract
Objective To examine the utility of a low-dose estrogen and pulsed progestogen hormone replacement therapy (HRT) regimen for add-back during long-term gonadotropin-releasing hormone-agonist (GnRH-agonist) therapy. Design A pilot clinical trial conducted at a tertiary referral, academic, reproductive sciences center. The study included 15 patients with endometriosis and 5 patients with severe premenstrual syndrome (PMS). Patients with endometriosis received leuprolide acetate depot 3.75 mg IM monthly until their symptoms had resolved (2-3 months), at which time HRT was initiated along with the GnRH-agonist. Patients with severe PMS received the same treatment with the addition of HRT after 1 month. The HRT regimen consisted of 1 mg oral micronized estradiol daily and 0.35 mg norethindrone daily for 2 days alternating with 2 days without norethindrone. The main outcome measure included bone density assessment in the lumbar spine and femoral neck by dual-energy x-ray absorptiometry at 6- to 12-month intervals. The mean follow-up duration +/- SD while on GnRH-agonist treatment was 31.2 +/- 17 months (for endometriosis patients) and 37.7 +/- 8.4 months (for patients with severe PMS). Results Bone mineral density was stable after initiation of HRT for the entire follow-up period. No patient had return of pelvic pain or resumption of mood swings after HRT add-back. After the first 3 months of HRT, all women remained amenorrheic. Conclusions Long-term GnRH-agonist down-regulation is…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Some clinical trials and cohort studies have demonstrated that a GnRH-a plus steroid add-back therapy can be effective from 30 months to up to 10 years [171, 172].”
From Hormonal treatments for endometriosis: The endocrine background (2022) · cites this paper as [171]
Citations
Cites
Strathy, J. H., Molgaard, C. A., Coulam, C. B., & Melton, L. J. (1982) · Fertility and Sterility · doi:10.1016/s0015-0282(16)46691-4 · Cited by 425
Administration of Nasal Nafarelin as Compared with Oral Danazol for Endometriosis
Henzl, M. R., Corson, S. L., Moghissi, K., Buttram, V. C., Berqvist, C., & Jacobson, J. (1988) · New England Journal of Medicine · doi:10.1056/nejm198802253180805 · Cited by 361
Dlugi, A. M., Miller, J. D., & Knittle, J. (1990) · Fertility and Sterility · doi:10.1016/s0015-0282(16)53755-8 · Cited by 279
The Premenstrual Syndrome: Effects of Medical Ovariectomy
Muse, K. N., Cetel, N. S., Futterman, L. A., & Yen, S. S. C. (1984) · New England Journal of Medicine · doi:10.1056/nejm198411223112104 · Cited by 268
Gonadotropin-releasing hormone analogues for the treatment of endometriosis: long-term follow-up
Waller, K. G., & Shaw, R. W. (1993) · Fertility and Sterility · doi:10.1016/s0015-0282(16)55791-4 · Cited by 252
Leuprolide Acetate Depot and Hormonal Add-Back in Endometriosis: A 12-Month Study
Hornstein, M. (1998) · Obstetrics & Gynecology · doi:10.1016/s0029-7844(97)00620-0 · Cited by 243
Lemay, A., Maheux, R., Faure, N., Jean, C., & Fazekas, A. T. A. (1984) · Fertility and Sterility · doi:10.1016/s0015-0282(16)47899-4 · Cited by 209
Androgen treatment prevents loss of cancellous bone in the orchidectomized rat
Wakley, G. K., Schutte, H. D., Hannon, K. S., & Turner, R. T. (1991) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650060403 · Cited by 190
Hammarbäck, S., & Bäckström, T. (1988) · Acta Obstetricia et Gynecologica Scandinavica · doi:10.3109/00016348809004191 · Cited by 163
Treatment of endometriosis with a long-acting gonadotropin-releasing hormone agonist.
Steingold, K. A., Cedars, M. I., Lu, J. K. H., Randle, D., Judd, H. L., & Meldrum, D. R. (1987) · PubMed · Cited by 131
Research works printed but not linked: 6
- Casper, 1991, CMAJ, 144, 153
- Verkauf, 1987, J Fla Med Assoc, 74, 671
- Pickersgill, 1998, Br J Obstet Gynaecol, 105, 475, 10.1111/j.1471-0528.1998.tb10146.x · DOI
- Casper, 1996, J Soc Gynecol Investig, 3, 225, 10.1177/107155769600300501 · doi:10.1177/107155769600300501
- Steingold, 1987, Obstet Gynecol, 69, 403
- Warnock, 1997, Psychopharmacol Bull, 33, 311
Cited by
Hormonal treatments for endometriosis: The endocrine background
Vannuccini, S., Clemenza, S., Rossi, M., & Petraglia, F. (2022) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-021-09666-w · Cited by 336
ISPMD consensus on the management of premenstrual disorders
Consensus Group of the International Society for Premenstrual Disorders, Nevatte, T., O’Brien, P. M. S., Bäckström, T., Brown, C., Dennerstein, L., Endicott, J., Epperson, C. N., Eriksson, E., Freeman, E. W., et al. (2013) · Archives of Women s Mental Health · doi:10.1007/s00737-013-0346-y · Cited by 211
Medication-induced osteoporosis: screening and treatment strategies
Panday, K., Gona, A., & Humphrey, M. B. (2014) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x14546350 · Cited by 201
Vercellini, P., Pietropaolo, G., De Giorgi, O., Pasin, R., Chiodini, A., & Crosignani, P. G. (2005) · Fertility and Sterility · doi:10.1016/j.fertnstert.2005.03.083 · Cited by 197
Premenstrual Dysphoric Disorder: Burden of Illness and Treatment Update
Pearlstein, T., & Steiner, M. (2012) · Focus · doi:10.1176/appi.focus.10.1.90 · Cited by 186
Metadata
- Authors
- Mitwally, M. F. M., Gotlieb, L., & Casper, R. F.
- Affiliations
- Mount Sinai Hospital (CA)
- ORCID
- Casper, Robert F.
- Venue
- Menopause
- Published
- 2002-07
- Volume
- 9
- Issue
- 4
- Pages
- 236-241
- ISSN
- 1072-3714 (ISSN-L)
- OpenAlex
- W1971380616
- Cited by
- 53
- References
- 42
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 1 · 2023: 3 · 2022: 3 · 2021: 2 · 2019: 1 · 2017: 1 · 2016: 2 · 2015: 2 · 2014: 2 · 2013: 2 · 2012: 3
- FWCI
- 3.72
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Menopause The Journal of The North American Menopause Society (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Keywords
- endometriosis, premenstrual syndrome, bone mineral density, estrogen replacement therapy, micronized estradiol, norethisterone, leuprolide, GnRH agonist down-regulation, estrogen deficiency, amenorrhea, bone loss prevention
- MeSH terms
- Administration, Oral, Adolescent, Adult, Delayed-Action Preparations, Densitometry, Drug Administration Schedule, Drug Therapy, Combination, Endometriosis, Estradiol, Female, Follow-Up Studies, Humans, Middle Aged, Osteoporosis, Pilot Projects, Premenstrual Syndrome, Reference Values, Severity of Illness Index, Bone Density, Leuprolide, Treatment Outcome, Hormone Replacement Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prevention of bone loss and hypoestrogenic symptoms by estrogen and interrupted progestogen add-back in long-term GnRH-agonist down-regulated patients with endometriosis and premenstrual syndrome. https://app.cochat.ai/papers/10.1097/00042192-200207000-00004
- The paper
- Mitwally, M. F. M., Gotlieb, L., & Casper, R. F. (2002). Prevention of bone loss and hypoestrogenic symptoms by estrogen and interrupted progestogen add-back in long-term GnRH-agonist down-regulated patients with endometriosis and premenstrual syndrome. Menopause. https://doi.org/10.1097/00042192-200207000-00004
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.